Stocks / NASDAQ / Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.

Our Opinion

Medicenna Therapeutics Corp. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“The majority of development has been focused on the MDNA109 platform candidates where promising results have been demonstrated in various animal tumour models, as described below.” (Page 23) Read the full document

Company Description

Medicenna Therapeutics Corp. is a clinical stage immunotherapy company. The Company is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases.

Company Website: